Risk of second primary thyroid cancer in cancer survivors.
Risk
SEER database
Second primary thyroid cancer
Standardized incidence ratios
Survival
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 05 2024
30 05 2024
Historique:
received:
09
07
2023
accepted:
25
05
2024
medline:
31
5
2024
pubmed:
31
5
2024
entrez:
30
5
2024
Statut:
epublish
Résumé
A risk factor for thyroid cancer (TC) may be a history of former cancer and cancer therapy. The precise risk of a second primary thyroid carcinoma has not yet been revealed. In this study, we evaluated standardized incidence ratios (SIRs) of second primary thyroid cancer (SPTC) with consideration of different conditions and further analyzed the clinicopathological characteristics and survival of these patients. The cohort was selected from the US Surveillance, Epidemiology, and End Results (SEER) Program between 1975 and 2019. The standardized incidence ratios, morbidity risk, clinicopathological features, and survival of second primary thyroid carcinoma were analyzed. Propensity score matching (PSM) was used to balance covariates. Kaplan-Meier method was performed to assess the survival outcomes. Overall, 7066 patients with SPTC and 83,113 patients with primary TC were identified. The SIR of TC in tumor patients was 1.51/10,000, statistically higher than the natural population (0.94/10,000, P < 0.05). The most significant tumors contributing to the increased SIRs of SPTC were acute lymphocytic leukemia (3.49/10,000), Hodgkin's lymphoma-nodal (3.29/10,000), salivary gland cancer (3.23/10,000), and kidney and renal pelvis cancer (3.05/10,000). The incidence of TC increased significantly in tumor patients who received radiotherapy/chemotherapy before age 35. The age at diagnosis of the SPTC was much older than the primary TC (64.01 vs. 49.55 years, p < 0.001). The SPTC had a higher percentage of histological grades 3/4 (23.14% vs. 15.19%, p < 0.001). Survival analyses demonstrated a worse prognosis for the SPTC group compared to the primary TC group. But after PSM, the survival outcomes of the two groups tended to be equivalent (P = 0.584). The SIRs of TC are higher in tumor patients. The most significant factors contributing to the increased risk of SPTC were some specific former tumors and acceptance of radiotherapy/ chemotherapy before age 35. There was no significant difference in survival between SPTC and primary TC.
Identifiants
pubmed: 38816510
doi: 10.1038/s41598-024-63155-z
pii: 10.1038/s41598-024-63155-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12478Informations de copyright
© 2024. The Author(s).
Références
Lim, H., Devesa, S. S., Sosa, J. A., Check, D. & Kitahara, C. M. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317, 1338–1348. https://doi.org/10.1001/jama.2017.2719 (2017).
doi: 10.1001/jama.2017.2719
pubmed: 28362912
pmcid: 8216772
Vaccarella, S. et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: A population-based study. Lancet Diabetes Endocrinol. 9, 144–152. https://doi.org/10.1016/s2213-8587(20)30401-0 (2021).
doi: 10.1016/s2213-8587(20)30401-0
pubmed: 33482107
Hussein, M. et al. Latency trend analysis as a guide to screening malignancy survivors for second primary thyroid cancer. Biomedicines https://doi.org/10.3390/biomedicines10081984 (2022).
doi: 10.3390/biomedicines10081984
pubmed: 36551844
pmcid: 9775843
Schonfeld, S. J., Morton, L. M., Berrington de González, A., Curtis, R. E. & Kitahara, C. M. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000–2015. Cancer Epidemiol. 64, 101664. https://doi.org/10.1016/j.canep.2019.101664 (2020).
doi: 10.1016/j.canep.2019.101664
pubmed: 31884334
Piek, M. W. et al. The co-occurrence of both breast- and differentiated thyroid cancer: Incidence, association and clinical implications for daily practice. BMC Cancer 22, 1018. https://doi.org/10.1186/s12885-022-10069-6 (2022).
doi: 10.1186/s12885-022-10069-6
pubmed: 36163009
pmcid: 9511724
Li, S. et al. Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: An analysis of the SEER database. BMC Public Health 19, 1592. https://doi.org/10.1186/s12889-019-7947-y (2019).
doi: 10.1186/s12889-019-7947-y
pubmed: 31783815
pmcid: 6884836
Nielsen, S. M. et al. The breast-thyroid cancer link: A systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 25, 231–238. https://doi.org/10.1158/1055-9965.Epi-15-0833 (2016).
doi: 10.1158/1055-9965.Epi-15-0833
Cieszyńska, M. et al. Risk of second primary thyroid cancer in women with breast cancer. Cancers (Basel) https://doi.org/10.3390/cancers14040957 (2022).
doi: 10.3390/cancers14040957
pubmed: 35205705
Kamran, S. C., Berrington de Gonzalez, A., Ng, A., Haas-Kogan, D. & Viswanathan, A. N. Therapeutic radiation and the potential risk of second malignancies. Cancer 122, 1809–1821. https://doi.org/10.1002/cncr.29841 (2016).
doi: 10.1002/cncr.29841
pubmed: 26950597
Taylor, A. J. et al. Risk of thyroid cancer in survivors of childhood cancer: Results from the British Childhood Cancer Survivor Study. Int. J. Cancer 125, 2400–2405. https://doi.org/10.1002/ijc.24581 (2009).
doi: 10.1002/ijc.24581
pubmed: 19610069
Cuellar Cuellar, A. A., Cuellar Rivera, D. I., Fierro-Maya, L. F. & Posso, V. H. Exposure to radiotherapy for first primary cancer as a risk factor for second primary thyroid cancer: A case-control study. Ann. Endocrinol. (Paris) 81, 539–544. https://doi.org/10.1016/j.ando.2020.11.005 (2020).
doi: 10.1016/j.ando.2020.11.005
pubmed: 33290749
Bhatti, P. et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: An update from the childhood cancer survivor study. Radiat. Res. 174, 741–752. https://doi.org/10.1667/rr2240.1 (2010).
doi: 10.1667/rr2240.1
pubmed: 21128798
pmcid: 3080023
Veiga, L. H. et al. Chemotherapy and thyroid cancer risk: A report from the childhood cancer survivor study. Cancer Epidemiol. Biomark. Prev. 21, 92–101. https://doi.org/10.1158/1055-9965.Epi-11-0576 (2012).
doi: 10.1158/1055-9965.Epi-11-0576
Polednik, K. M. et al. Radiation and second primary thyroid cancer following index head and neck cancer. Laryngoscope 129, 1014–1020. https://doi.org/10.1002/lary.27467 (2019).
doi: 10.1002/lary.27467
pubmed: 30208210
Trinh, L. N. et al. Deciphering the risk of developing second primary thyroid cancer following a primary malignancy-who is at the greatest risk?. Cancers (Basel) https://doi.org/10.3390/cancers13061402 (2021).
doi: 10.3390/cancers13061402
pubmed: 34572883
Lu, M., Liu, H., Zheng, B., Sun, S. & Chen, C. Links between breast and thyroid cancer: Hormones, genetic susceptibility and medical interventions. Cancers (Basel) https://doi.org/10.3390/cancers14205117 (2022).
doi: 10.3390/cancers14205117
pubmed: 36612194
pmcid: 9657017
Hancock, S. L., McDougall, I. R. & Constine, L. S. Thyroid abnormalities after therapeutic external radiation. Int. J. Radiat. Oncol. Biol. Phys. 31, 1165–1170. https://doi.org/10.1016/0360-3016(95)00019-u (1995).
doi: 10.1016/0360-3016(95)00019-u
pubmed: 7713780
Pasqual, E. et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies. J. Clin. Oncol. 40, 1439–1449. https://doi.org/10.1200/jco.21.01841 (2022).
doi: 10.1200/jco.21.01841
pubmed: 35044839
pmcid: 9061144
Giannoula, E., Gkantaifi, A. & Iakovou, I. Radiation treatment of head and neck carcinomas as a risk factor for thyroid carcinomas. Hell. J. Nucl. Med. 19, 65–74. https://doi.org/10.1967/s002449910343 (2016).
doi: 10.1967/s002449910343
pubmed: 26929946
Chow, E. J. et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Pediatr. Blood Cancer 53, 432–437. https://doi.org/10.1002/pbc.22082 (2009).
doi: 10.1002/pbc.22082
pubmed: 19459201
pmcid: 2713362
Yang, Z., Liu, X., Yang, X. & Liao, Q. P. Second primary malignancies after ovarian cancer: A SEER-based analysis (1975–2016). Taiwan J. Obstet. Gynecol. 61, 80–85. https://doi.org/10.1016/j.tjog.2021.11.015 (2022).
doi: 10.1016/j.tjog.2021.11.015
pubmed: 35181052
Lal, G. et al. Risk of subsequent primary thyroid cancer after another malignancy: Latency trends in a population-based study. Ann. Surg. Oncol. 19, 1887–1896. https://doi.org/10.1245/s10434-011-2193-2 (2012).
doi: 10.1245/s10434-011-2193-2
pubmed: 22227921
pmcid: 4372195